-
Something wrong with this record ?
Efficacy, safety, and drug survival of patients with psoriasis treated with IL-17 inhibitors - brodalumab, ixekizumab, and secukinumab: real-world data from the Czech Republic BIOREP registry
M. Kojanova, J. Hugo, B. Velackova, P. Cetkovska, J. Fialova, T. Dolezal, M. Tichy, S. Gkalpakiotis, BIOREP study group
Language English Country England, Great Britain
Document type Journal Article
- MeSH
- Interleukin-17 * MeSH
- Humans MeSH
- Antibodies, Monoclonal adverse effects MeSH
- Psoriasis * drug therapy chemically induced MeSH
- Registries MeSH
- Retrospective Studies MeSH
- Severity of Illness Index MeSH
- Treatment Outcome MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Geographicals
- Czech Republic MeSH
BACKGROUND: Real-world data on the use of interleukin-17 (IL-17) inhibitors for the treatment of psoriasis are limited. OBJECTIVE: To evaluate and compare the efficacy, safety, and drug survival of IL-17 inhibitors. METHODS: This retrospective study analyzed the BIOREP registry data of patients treated with at least one IL-17 inhibitor (secukinumab, ixekizumab, and brodalumab). RESULTS: In total, 949 patients were included. The improvement in PASI score was significant for all drugs, and the proportion of patients achieving PASI 75, 90, and 100 after both 3 and 24 months of therapy was highest for brodalumab, followed by ixekizumab and secukinumab. The Dermatology Life Quality Index score decreased to ˂3 after 3 months and to ˂2 after 24 months of therapy for all inhibitors. Loss of effectiveness was the major reason for discontinuation in 17.2% of patients, followed by adverse events in 3.2% of patients. The drug survival probability was the highest for brodalumab, followed by ixekizumab and secukinumab. Negative predictors for treatment discontinuation were obesity and the number of treatment lines, whereas a positive predictor was the presence of concomitant psoriatic arthritis; sex had no influence. CONCLUSION: This real-life study demonstrated the effectiveness and good safety profile of all currently available IL-17 inhibitors.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22033327
- 003
- CZ-PrNML
- 005
- 20230131150930.0
- 007
- ta
- 008
- 230120s2022 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1080/09546634.2022.2082354 $2 doi
- 035 __
- $a (PubMed)35635185
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Kojanova, Martina $u Department of Dermatovenereology, First Faculty of Medicine and General University Hospital, Charles University, Prague, Czech Republic $1 https://orcid.org/0000000198909965
- 245 10
- $a Efficacy, safety, and drug survival of patients with psoriasis treated with IL-17 inhibitors - brodalumab, ixekizumab, and secukinumab: real-world data from the Czech Republic BIOREP registry / $c M. Kojanova, J. Hugo, B. Velackova, P. Cetkovska, J. Fialova, T. Dolezal, M. Tichy, S. Gkalpakiotis, BIOREP study group
- 520 9_
- $a BACKGROUND: Real-world data on the use of interleukin-17 (IL-17) inhibitors for the treatment of psoriasis are limited. OBJECTIVE: To evaluate and compare the efficacy, safety, and drug survival of IL-17 inhibitors. METHODS: This retrospective study analyzed the BIOREP registry data of patients treated with at least one IL-17 inhibitor (secukinumab, ixekizumab, and brodalumab). RESULTS: In total, 949 patients were included. The improvement in PASI score was significant for all drugs, and the proportion of patients achieving PASI 75, 90, and 100 after both 3 and 24 months of therapy was highest for brodalumab, followed by ixekizumab and secukinumab. The Dermatology Life Quality Index score decreased to ˂3 after 3 months and to ˂2 after 24 months of therapy for all inhibitors. Loss of effectiveness was the major reason for discontinuation in 17.2% of patients, followed by adverse events in 3.2% of patients. The drug survival probability was the highest for brodalumab, followed by ixekizumab and secukinumab. Negative predictors for treatment discontinuation were obesity and the number of treatment lines, whereas a positive predictor was the presence of concomitant psoriatic arthritis; sex had no influence. CONCLUSION: This real-life study demonstrated the effectiveness and good safety profile of all currently available IL-17 inhibitors.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a interleukin-17 $7 D020381
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a monoklonální protilátky $x škodlivé účinky $7 D000911
- 650 12
- $a psoriáza $x farmakoterapie $x chemicky indukované $7 D011565
- 650 _2
- $a registrace $7 D012042
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a stupeň závažnosti nemoci $7 D012720
- 651 _2
- $a Česká republika $7 D018153
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Hugo, Jan $u Department of Dermatovenereology, Third Faculty of Medicine, Charles University and Kralovske Vinohrady University Hospital, Prague, Czech Republic
- 700 1_
- $a Velackova, Barbora $u Value Outcomes, Prague, Czech Republic
- 700 1_
- $a Cetkovska, Petra $u Department of Dermatovenereology, Faculty of Medicine in Pilsen, Charles University, Prague, Czech Republic
- 700 1_
- $a Fialova, Jorga $u Department of Dermatovenereology, First Faculty of Medicine and General University Hospital, Charles University, Prague, Czech Republic
- 700 1_
- $a Dolezal, Tomas $u Value Outcomes, Prague, Czech Republic
- 700 1_
- $a Tichy, Martin $u Department of Dermatology and Venereology, Faculty of Medicine and Dentistry, University Hospital Olomouc, Olomouc, Czech Republic
- 700 1_
- $a Gkalpakiotis, Spyridon $u Department of Dermatovenereology, Third Faculty of Medicine, Charles University and Kralovske Vinohrady University Hospital, Prague, Czech Republic $1 https://orcid.org/0000000269565961
- 710 2_
- $a BIOREP study group
- 773 0_
- $w MED00004913 $t The Journal of dermatological treatment $x 1471-1753 $g Roč. 33, č. 6 (2022), s. 2827-2837
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/35635185 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230120 $b ABA008
- 991 __
- $a 20230131150926 $b ABA008
- 999 __
- $a ok $b bmc $g 1891864 $s 1184662
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2022 $b 33 $c 6 $d 2827-2837 $e 20220529 $i 1471-1753 $m Journal of dermatological treatment $n J Dermatolog Treat $x MED00004913
- LZP __
- $a Pubmed-20230120
